RESEARCH TRIANGLE PARK, N.C. – The Hamner Institutes for Health Sciences (www.thehamner.org) will present one paper and two posters at the 2008 Respiratory Drug Delivery (RDD) Conference on May 11-15 at the Westin Kierland Resort & Spa in Scottsdale, Ariz. The Hamner scientists presenting at the 2008 RDD Conference are:
Bahman Asgharian, Ph.D., associate investigator, Division of Computational Biology at The Hamner • Poster Topic: Preferential Deposition of Inhaled Particles in the Lung by Controlling Particle Properties
Guilherme Garcia, Ph.D., postdoctoral fellow in Biomedical Engineering and Fluid Mechanics at The Hamner • Paper Topic: Inter-human Variability in Nasal Filtration of Inhaled Particles Among Nasal Replicas of Four Healthy Individuals
Jeffry D. Schroeter, Ph.D., research investigator, Division of Computation Biology at The Hamner • Poster Topic: Experimental and Computational Predictions of Particle Deposition in a Sectional Human Nasal Model
Dr. Schroeter’s poster abstract was selected as one of top posters submitted for the 2008 Conference. In addition to presenting his work in the paper format, he will present a summary of his data and conclusions during the event’s “Posters on the Podium” (POP) session on Tuesday, May 13, 2-3 p.m. in the Kierland Grand Ballroom. More than 150 posters were submitted for review. Only the top 5 were selected for the 2008 POP session.
Each of the presenting scientists from The Hamner focus their research in the organization’s Center for Drug Safety Sciences, one of four coordinated Centers within The Hamner Institutes for Health Sciences. The Center for Drug Safety Sciences applies a systems biology approach to define, integrate and disseminate knowledge of the basic biology of disease and adverse drug effects in order to improve safety and public health decision making and advance the development of new and safe medicines.
The biannual USA RDD conference is the industry’s leading event for scientists, managers and regulatory experts interested in the science, development, testing and regulations applied to nasal and pulmonary products. The conference plays host to a number of in-depth discussions on developing issues surrounding aerosol drug delivery, including new therapeutic opportunities and drug design technologies, progress in drug development alongside novel in vitro and in vivo testing methods, regulatory science, among others. More than 700 attendees are expected.
